Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients

Min Ling, Kwaku Marfo, Peter Masiakos, Aws Aljanabi, Joel Lindower, Daniel Glicklich, Graciela D. de Boccardo, Stuart M. Greenstein, Javier Chapochnick-Friedmann, Liise Kayler, Milan Kinkhabwala, Enver Akalin

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We investigated the prevalence and the strength of anti-HLA-Cw and DP antibodies and clinical outcomes in kidney transplant recipients with isolated donor-specific anti-HLA-Cw antibodies. Patients on the waiting list were screened by Luminex single antigen beads (One Lambda). The strength of antibodies was determined by mean fluorescence intensity (MFI) values of the beads. Of the 1069 patients on the waiting list, 251 (24%) were sensitized with calculated panel reactive antibody >0%. The frequency and the median MFI values of anti-HLA antibodies to Cw (56%, 4955) and DP (35%, 2945) were lower than anti-HLA-A (79%, 10,194), B (86%, 11,235), DR (66%, 7866) and DQ (69%, 8283) (p<0.01). Among three major sensitizing events, only previous transplant was associated with development of all anti-HLA antibodies and history of pregnancy was associated only with development of anti-HLA-A antibodies. Eight patients with donor-specific anti-HLA-Cw antibodies received transplantation. During a median 6. months of follow-up (range 3-24. months), patient and graft survival was 100% without any acute rejection. In summary, the prevalence and the strength of anti-HLA-Cw and HLA-DP were lower compared to anti-HLA-A, B, DR, and DQ antibodies and previous organ transplantation was the main sensitizing event in our cohort of patients.

Original languageEnglish (US)
Pages (from-to)879-883
Number of pages5
JournalHuman Immunology
Volume73
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

HLA-DP Antigens
Antibodies
HLA-A Antigens
Waiting Lists
Anti-Idiotypic Antibodies
Fluorescence
Tissue Donors
Reproductive History
HLA-B Antigens
Organ Transplantation
Graft Survival
Transplantation
Transplants
Kidney
Antigens

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Ling, M., Marfo, K., Masiakos, P., Aljanabi, A., Lindower, J., Glicklich, D., ... Akalin, E. (2012). Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients. Human Immunology, 73(9), 879-883. https://doi.org/10.1016/j.humimm.2012.07.320

Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients. / Ling, Min; Marfo, Kwaku; Masiakos, Peter; Aljanabi, Aws; Lindower, Joel; Glicklich, Daniel; de Boccardo, Graciela D.; Greenstein, Stuart M.; Chapochnick-Friedmann, Javier; Kayler, Liise; Kinkhabwala, Milan; Akalin, Enver.

In: Human Immunology, Vol. 73, No. 9, 09.2012, p. 879-883.

Research output: Contribution to journalArticle

Ling, M, Marfo, K, Masiakos, P, Aljanabi, A, Lindower, J, Glicklich, D, de Boccardo, GD, Greenstein, SM, Chapochnick-Friedmann, J, Kayler, L, Kinkhabwala, M & Akalin, E 2012, 'Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients', Human Immunology, vol. 73, no. 9, pp. 879-883. https://doi.org/10.1016/j.humimm.2012.07.320
Ling M, Marfo K, Masiakos P, Aljanabi A, Lindower J, Glicklich D et al. Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients. Human Immunology. 2012 Sep;73(9):879-883. https://doi.org/10.1016/j.humimm.2012.07.320
Ling, Min ; Marfo, Kwaku ; Masiakos, Peter ; Aljanabi, Aws ; Lindower, Joel ; Glicklich, Daniel ; de Boccardo, Graciela D. ; Greenstein, Stuart M. ; Chapochnick-Friedmann, Javier ; Kayler, Liise ; Kinkhabwala, Milan ; Akalin, Enver. / Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients. In: Human Immunology. 2012 ; Vol. 73, No. 9. pp. 879-883.
@article{081f0323151e48bb88668fc7f59c938b,
title = "Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients",
abstract = "We investigated the prevalence and the strength of anti-HLA-Cw and DP antibodies and clinical outcomes in kidney transplant recipients with isolated donor-specific anti-HLA-Cw antibodies. Patients on the waiting list were screened by Luminex single antigen beads (One Lambda). The strength of antibodies was determined by mean fluorescence intensity (MFI) values of the beads. Of the 1069 patients on the waiting list, 251 (24{\%}) were sensitized with calculated panel reactive antibody >0{\%}. The frequency and the median MFI values of anti-HLA antibodies to Cw (56{\%}, 4955) and DP (35{\%}, 2945) were lower than anti-HLA-A (79{\%}, 10,194), B (86{\%}, 11,235), DR (66{\%}, 7866) and DQ (69{\%}, 8283) (p<0.01). Among three major sensitizing events, only previous transplant was associated with development of all anti-HLA antibodies and history of pregnancy was associated only with development of anti-HLA-A antibodies. Eight patients with donor-specific anti-HLA-Cw antibodies received transplantation. During a median 6. months of follow-up (range 3-24. months), patient and graft survival was 100{\%} without any acute rejection. In summary, the prevalence and the strength of anti-HLA-Cw and HLA-DP were lower compared to anti-HLA-A, B, DR, and DQ antibodies and previous organ transplantation was the main sensitizing event in our cohort of patients.",
author = "Min Ling and Kwaku Marfo and Peter Masiakos and Aws Aljanabi and Joel Lindower and Daniel Glicklich and {de Boccardo}, {Graciela D.} and Greenstein, {Stuart M.} and Javier Chapochnick-Friedmann and Liise Kayler and Milan Kinkhabwala and Enver Akalin",
year = "2012",
month = "9",
doi = "10.1016/j.humimm.2012.07.320",
language = "English (US)",
volume = "73",
pages = "879--883",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients

AU - Ling, Min

AU - Marfo, Kwaku

AU - Masiakos, Peter

AU - Aljanabi, Aws

AU - Lindower, Joel

AU - Glicklich, Daniel

AU - de Boccardo, Graciela D.

AU - Greenstein, Stuart M.

AU - Chapochnick-Friedmann, Javier

AU - Kayler, Liise

AU - Kinkhabwala, Milan

AU - Akalin, Enver

PY - 2012/9

Y1 - 2012/9

N2 - We investigated the prevalence and the strength of anti-HLA-Cw and DP antibodies and clinical outcomes in kidney transplant recipients with isolated donor-specific anti-HLA-Cw antibodies. Patients on the waiting list were screened by Luminex single antigen beads (One Lambda). The strength of antibodies was determined by mean fluorescence intensity (MFI) values of the beads. Of the 1069 patients on the waiting list, 251 (24%) were sensitized with calculated panel reactive antibody >0%. The frequency and the median MFI values of anti-HLA antibodies to Cw (56%, 4955) and DP (35%, 2945) were lower than anti-HLA-A (79%, 10,194), B (86%, 11,235), DR (66%, 7866) and DQ (69%, 8283) (p<0.01). Among three major sensitizing events, only previous transplant was associated with development of all anti-HLA antibodies and history of pregnancy was associated only with development of anti-HLA-A antibodies. Eight patients with donor-specific anti-HLA-Cw antibodies received transplantation. During a median 6. months of follow-up (range 3-24. months), patient and graft survival was 100% without any acute rejection. In summary, the prevalence and the strength of anti-HLA-Cw and HLA-DP were lower compared to anti-HLA-A, B, DR, and DQ antibodies and previous organ transplantation was the main sensitizing event in our cohort of patients.

AB - We investigated the prevalence and the strength of anti-HLA-Cw and DP antibodies and clinical outcomes in kidney transplant recipients with isolated donor-specific anti-HLA-Cw antibodies. Patients on the waiting list were screened by Luminex single antigen beads (One Lambda). The strength of antibodies was determined by mean fluorescence intensity (MFI) values of the beads. Of the 1069 patients on the waiting list, 251 (24%) were sensitized with calculated panel reactive antibody >0%. The frequency and the median MFI values of anti-HLA antibodies to Cw (56%, 4955) and DP (35%, 2945) were lower than anti-HLA-A (79%, 10,194), B (86%, 11,235), DR (66%, 7866) and DQ (69%, 8283) (p<0.01). Among three major sensitizing events, only previous transplant was associated with development of all anti-HLA antibodies and history of pregnancy was associated only with development of anti-HLA-A antibodies. Eight patients with donor-specific anti-HLA-Cw antibodies received transplantation. During a median 6. months of follow-up (range 3-24. months), patient and graft survival was 100% without any acute rejection. In summary, the prevalence and the strength of anti-HLA-Cw and HLA-DP were lower compared to anti-HLA-A, B, DR, and DQ antibodies and previous organ transplantation was the main sensitizing event in our cohort of patients.

UR - http://www.scopus.com/inward/record.url?scp=84865356810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865356810&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2012.07.320

DO - 10.1016/j.humimm.2012.07.320

M3 - Article

C2 - 22841893

AN - SCOPUS:84865356810

VL - 73

SP - 879

EP - 883

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 9

ER -